Home » Stocks » EyeGate Pharmaceuticals

EyeGate Pharmaceuticals, Inc. (EYEG)

Stock Price: $5.31 USD -0.30 (-5.27%)
Updated Aug 14, 2020 1:12 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 24.54M
Revenue (ttm) n/a
Net Income (ttm) -9.80M
Shares Out 4.63M
EPS (ttm) -2.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $5.31
Previous Close $5.60
Change ($) -0.30
Change (%) -5.27%
Day's Open 5.60
Day's Range 5.20 - 5.61
Day's Volume 80,821
52-Week Range 2.25 - 12.89

More Stats

Market Cap 24.54M
Enterprise Value 20.19M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 4.63M
Float 2.64M
EPS (basic) -2.72
EPS (diluted) -2.46
FCF / Share -1.86
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10,319
Short Ratio 0.42
Short % of Float 0.45%
Beta 1.53
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.43
Revenue n/a
Operating Income -9.76M
Net Income -9.80M
Free Cash Flow -8.45M
Net Cash 4.35M
Net Cash / Share 0.94
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -52.94%
ROE -120.47%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(110.56% upside)
Current: $5.31
Target: 11.17
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth62.54%305.51%-39.11%----
Gross Profit2.691.650.410.67---
Operating Income-7.11-10.84-14.56-13.35-6.68-2.46-3.10
Net Income-7.10-10.81-13.22-13.34-8.39-1.77-3.88
Shares Outstanding3.182.370.950.590.410.010.01
Earnings Per Share-2.23-4.57-13.95-22.65-40.50-137.99-315.43
Operating Cash Flow-8.15-10.84-6.47-8.41-4.46-0.95-2.96
Capital Expenditures--0.02-0.04----
Free Cash Flow-8.15-10.86-6.51-8.41-4.46-0.95-2.96
Cash & Equivalents3.828.057.853.688.410.170.53
Total Debt0.08--0.02-3.212.03
Net Cash / Debt3.748.057.853.668.41-3.04-1.50
Book Value6.628.94-1.93-0.336.09-53.59-51.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name EyeGate Pharmaceuticals, Inc.
Country United States
Employees 10
CEO Stephen From

Stock Information

Ticker Symbol EYEG
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EYEG


EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and anterior uveitis; and Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.